Philipps-Universität Marburg

LONG-TERM SAFETY OF CANAKINUMAB IN PATIENTS WITH AUTOINFLAMMATORY DISEASES - INTERIM ANALYSIS OF THE RELIANCE REGISTRY (2022) Kuemmerle-Deschner JB, Henes J, Kortus-Goetze B, Kallinich T, Oommen P, Rech J, Krickau T, et al. Conference contribution LONG-TERM EFFICACY AND SAFETY OF CANAKINUMAB IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER (FMF) - INTERIM ANALYSIS OF THE RELIANCE REGISTRY (2022) Henes J, Kuemmerle-Deschner JB, Krickau T, Kallinich T, Dressler F, Horneff G, Meier F, et al. Conference contribution AI Prediction of Neuropathic Pain after Lumbar Disc Herniation-Machine Learning Reveals Influencing Factors (2022) Wirries A, Geiger F, Hammad A, Baeumlein M, Schmeller JN, Blümcke I, Jabari S Journal article Current research and unmet needs in allergy and immunology in Germany: report presented by the DGfI and DGAKI task force Allergy & Immunology (2022) Albrecht M, Schaub B, Gilles S, Koehl J, Altrichter S, Vöhringer D, Spillner E, et al. Journal article, Editorial Positionspapier zur Befunderhebung von Darmultraschallbefunden bei chronisch entzündlichen Darmerkrankungen (2022) Kucharzik T, Atreya R, Bachmann O, Baumgart DC, Daebritz J, Helwig U, Janschek J, et al. Journal article Radical Resection in Entero-Pancreatic Neuroendocrine Tumors: Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence (2022) Merola E, Pascher A, Rinke A, Bartsch DK, Zerbi A, Nappo G, Carnaghi C, et al. Journal article Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations (2022) Eckardt JN, Stoelzel F, Kunadt D, Roellig C, Stasik S, Wagenfuehr L, Joehrens K, et al. Journal article Comparative analysis of machine learning algorithms for multi-syndrome classification of neurodegenerative syndromes (2022) Lampe L, Niehaus S, Huppertz HJ, Merola A, Reinelt J, Mueller K, Anderl-Straub S, et al. Journal article Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): Explorative analysis in Penelope-B (2022) Furlanetto J, Marme F, Thode C, Nekljudova V, Liu Y, Jimenez MM, Reimer T, et al. Conference contribution Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment (2022) Marme F, Hanusch C, Furlanetto J, Morris P, Link T, Denkert C, Fasching P, et al. Conference contribution